The Attention Deficit Disorder Partnering 2009-2014 provides understanding and access to the attention deficit disorder partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of attention deficit disorder partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors attention deficit disorder technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 35 links to online copies of actual attention deficit disorder deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of attention deficit disorder partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in attention deficit disorder partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading attention deficit disorder deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of attention deficit disorder partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of attention deficit disorder technologies and products.
Attention Deficit Disorder Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to anxiety trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in attention deficit disorder dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading attention deficit disorder deals by value since 2009 In Attention Deficit Disorder Partnering 2009-2014, the available deals are listed by:
Headline value Upfront payment value Royalty rate value Company A-Z Industry sector Stage of development at signing Deal component type Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Attention Deficit Disorder Partnering 2009-2014 provides the reader with the following key benefits:
In-depth understanding of attention deficit disorder deal trends since 2009 Access to summary headline, upfront, milestone and royalty data Comprehensive access to over 30 actual attention deficit disorder deals entered into by the world’s biopharma companies since 2009 Insight into key deal terms included in contracts, where disclosed Understand the key deal terms companies have agreed in deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in attention deficit disorder partnering
2.1. Introduction 2.2. Attention deficit disorder partnering over the years 2.3. Bigpharma attention deficit disorder dealmaking activity 2.4. Attention deficit disorder partnering by deal type 2.5. Attention deficit disorder partnering industry sector 2.6. Attention deficit disorder partnering by stage of development 2.7. Attention deficit disorder partnering by technology type 2.8. Disclosed financial deal terms for attention deficit disorder partnering 2.8.1 Attention deficit disorder headline values 2.8.2 Attention deficit disorder upfront payments 2.8.3 Attention deficit disorder milestone payments 2.8.4 Attention deficit disorder royalty rates Chapter 3 – Leading attention deficit disorder deals
3.1. Introduction 3.2. Top attention deficit disorder deals by value 3.3. Top attention deficit disorder deals involving bigpharma Chapter 4 – Dealmaking directory
4.1. Introduction 4.2. Company A-Z 4.3. By deal type Asset purchase Bigpharma outlicensing Co-development Collaborative R&D Co-market Contract service Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Option Promotion Research Settlement Spin out Sub-license Supply Termination 4.4. By industry sector Academic Bigpharma Biotech Drug delivery Medical device Diagnostic Generic pharma Government Non-profit Pharmaceutical Research tools Services Specialty pharma 4.5. By stage of development Discovery Pre-clinical Phase I Phase II Phase III Registration Marketed 4.6. By technology type Analysis Animal models Assays Bioinformatics Biological compounds Biomarkers Biomaterials Cell culture Cell therapy Clinical testing Diagnostic - companion Devices Diagnostics Discovery tools DNA probes Drug delivery Enabling technology Epigenetics Equipment Facilities Gene therapy Genomics Imaging Industrial chemicals In vitro models Monoclonal antibodies Nanotechnology Oligonucleotide Peptides Personalised medicine Processes Proteomics Radio/Chemo-therapy Recombinant DNA Research services Research supplies RNA therapeutics Screening Small molecules Stem cells Vaccines Chapter 5 – Partnering resource center
5.1. Online partnering 5.2. Partnering events 5.3. Further reading on dealmaking Appendices
Appendix 1 – Deal type definitions About Wildwood Ventures Current Partnering Current Agreements Recent titles from CurrentPartnering Order Form – Reports Table of figures
Figure 1: Attention deficit disorder partnering since 2009 Figure 2: Bigpharma – top 50 –Attention deficit disorder deals 2009 to 2011 Figure 3: Bigpharma attention deficit disorder deal frequency – 2009 to 2011 Figure 4: Attention deficit disorder partnering by deal type since 2009 Figure 5:Attention deficit disorder partnering by industry sector since 2009 Figure 6: Attention deficit disorder partnering by stage of development since 2009 Figure 7: Attention deficit disorder partnering by technology type since 2009 Figure 8: Attention deficit disorder deals with a headline value Figure 9: Attention deficit disorder deals with upfront payment values Figure 10: Attention deficit disorder deals with milestone payments Figure 11: Attention deficit disorder deals with royalty rates, % Figure 12: Top attention deficit disorder deals by value since 2009 Figure 13: Top attention deficit disorder deals signed by bigpharma value since 2009 Figure 14: Online partnering resources Figure 15: Forthcoming partnering events Figure 16: Deal type definitions $995: single-user $1,495: multi-user $2,995: single site license $4,975: global site license An annual subscription to quarterly updates can be purchased for a small additional fee; ensuring you are kept up-to-date with the very latest attention deficit disorder partnering deals. Quarterly updates available from $497.50.
A full explanation of license type definitions can be found here.
An additional $500 per copy will be added for full print and CD-ROM requests.